Overcoming docetaxel resistance in prostate cancer: a perspective review

  title={Overcoming docetaxel resistance in prostate cancer: a perspective review},
  author={Clara Hwang},
  booktitle={Therapeutic advances in medical oncology},
The treatment of metastatic castrate-resistant prostate cancer has been historically challenging, with few therapeutic successes. Docetaxel was the first cytotoxic therapy associated with a survival benefit in castrate-resistant prostate cancer. Toxicity is typical of other cytotoxic agents, with myelosuppression being the dose-limiting toxicity and neurotoxicity also a notable side effect for some patients. Unfortunately, a significant proportion of men with castrate-resistant prostate cancer… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 34 extracted citations


Publications referenced by this paper.
Showing 1-10 of 85 references

Overall survival benefit of radium-223 chloride (AlpharadinTM) in the treatment of patients with symptomatic bone metastases in castration resistant

  • C. Parker, D. Heidreich, J. M. O'Sullivan, S. D. Fossa, A. Chodacki, T Demkow
  • 2011
Highly Influential
4 Excerpts

Similar Papers

Loading similar papers…